Patients with SSc vs controls showed a greater prevalence of WMH on brain MRIs, particularly in deep white matter regions.

Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - ...

Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic ...

Objectives To assess vaccine effectiveness (VE) and safety of the recombinant zoster vaccine (RZV) in adults with systemic lupus erythematosus (SLE).Methods This retrospective study using ...

In June 2025, Cabaletta closed an underwritten public offering consisting of shares of its common stock, pre-funded warrants and accompanying common stock warrants. The net proceeds from the offering ...

Cash runway into Q2 2027, with cash, cash equivalents, and investments of $142.4 million as of June 30, 2025 ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

Puffy hands and fingers, as well as other symptoms, can precede the “warning sign” of Raynaud’s syndrome as the initial ...

A new interdisciplinary model for systemic sclerosis integrates imaging, AI, and personalized care to detect cardiac ...

A new study finds nearly 50% of systemic sclerosis patients show signs of ARFID, raising concerns about disordered eating linked to chronic GI symptoms.

Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s potential. Click for more on ZBIO stock.